Melanoma with Metastases to Lungs-

Share Button

I agree that Immunotherapy Can Be Transformative. But Are Yervoy, Keytruda, Nivolumab, “Transformative” in anything but the high cost of cancer therapy?

The media too often falls into the trap of hyping cancer therapies. While the immunotherapies Yervoy, Keytruda and Nivolomab may extend the overall survival of a small number of cancer survivors, these expensive chemotherapies

  • have serious potential side effects
  • are limited in Overall Survival and remission for the vast number of survivors
  • are NOT curative

Click the image below to learn more about skin cancer-

Skin Cancer Mind Map

Melanoma is a complicated cancer. Saying these therapies are “transforming” oncology is like saying the narrowing of field goal post in the NFL transformed football.

Do you even remember when the NFL first narrowed the width of goal posts? They want to do it again...

Yes, these drugs are another therapy for certain melanomas, lung cancers, and melanoma that have metastasized to the lungs. ¬†A small number of cancer patients have the exact molecular cancer make-up to benefit from Yervoy, Keytruda or Nivolomab. ¬†Unfortunately, immunotherapies only allow remissions for a limited time. These “transformative” chemotherapy regimens are not curative.

My experience as a cancer patient and cancer coach is that the key to living with metastatic melanoma is integrative therapies to combine the best of both conventional and non-conventional therapies.

Sorry if I am sounding a bit negative. My cousin, Peter Conard, 52, passed away last week. Peter was diagnosed with non-small cell lung cancer two years ago. Peter was a 52 year old non-smoker and one of the healthiest guys I know. Peter’s cancer went into remission when he went on Yervoy. Peter was determined to beat his cancer… Peter’s cancer experience was not transformative.

To learn more about both conventional and non-conventional cancer therapies, scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director of PeopleBeatingCancer

How the Promise of Immunotherapy Is Transforming Oncology

“It took some 700 patients and extended the trial to 2010. In the end, fewer than 10% met standard criteria for tumor shrinkage. But 23% survived at least three years, making the drug the first to ever show a survival benefit in patients with advanced melanoma. The drug, now owned by Bristol-Myers and known as Yervoy, was approved in 2011.

The challenge was to widen the benefit to more patients and more cancers.

The disease attracting intense interest is lung cancer, which causes more than 200,000 deaths a year in the U.S.”



Leave a Comment:

Add Your Reply